超低分次与常规分次放疗后10年泌尿生殖及胃肠道疾病常规健康数据对比
基于HYPO-RT-PC随机III期试验,链接瑞典国家医疗登记数据比较超低分次与常规分次放疗的10年泌尿生殖及胃肠道事件。两组间无显著差异,超低分次组调整后HR:泌尿生殖0.95(95%CI 0.71-1.25),胃肠道1.24(95%CI 0.91-1.69)。与未暴露男性相比,10年超额累积发生率4%-8%,无超额死亡。
要点
- 超低分次与常规分次放疗的10年泌尿生殖及胃肠道事件无统计学显著差异。
- 与未放疗男性相比,10年超额累积发生率4%-8%,无超额死亡事件。
- 常规收集健康数据可用于验证随机试验的长期安全性结论。
核心结论
- 超低分次放疗与常规分次放疗在10年泌尿生殖及胃肠道疾病发生上无统计学显著差异。
- 与未暴露男性相比,10年超额累积发生率为4%-8%,且无超额死亡事件。
研究设计与样本
- 随机、非劣效、III期HYPO-RT-PC试验的常规收集健康数据验证分析。
- 主要结局为将CTCAE v5.0映射至诊断和干预编码定义的泌尿生殖及胃肠道事件,分宽泛和严格编码集分别检验。
- 事件包括住院、干预和死因,来源于瑞典国家医疗登记,采用时间至事件分析并调整Charlson合并症指数和社会经济状态。
主要发现
- 放疗组间宽泛编码集调整后HR:泌尿生殖事件0.95(95%CI 0.71-1.25),胃肠道事件1.24(95%CI 0.91-1.69)。
- 与未暴露男性相比,10年超额累积发生率宽泛编码集泌尿生殖8%、胃肠道5%,严格编码集泌尿生殖5%、胃肠道4%。
- 无超额死亡事件。
临床怎么用
- 支持超低分次放疗在局部前列腺癌中的长期安全性,可作为常规分次放疗的替代选择。
- 常规收集健康数据可用于补充随机试验的长期毒性评估。
局限性
- 仅纳入瑞典居民,外推性需谨慎。
- 暴露组间比较基于符合方案人群,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: HYPO-RT-PC was the first phase 3 trial showing the long-term efficacy and safety of extremely hypofractionated radiotherapy schedules (ultra-hypofractionation or stereotactic body radiotherapy) compared with standard radiotherapy in localised prostate cancer. We aimed to verify their safety in the context of a clinical trial, by comparing events of potentially radiotherapy-related morbidity according to routinely collected health data between the arms and with men unexposed to prostate radiotherapy. MATERIALS AND METHODS: We included Swedish residents in the per-protocol population and unexposed men matched with the ultra-hypofractionation group. Primary outcomes were genitourinary and gastrointestinal events defined by linking the Common Terminology Criteria for Adverse Events version 5.0 to diagnosis and intervention codes in broad (any related condition) and narrow code sets (strongly related conditions) tested separately. Inpatient care, interventions, and causes of death, identified in Swedish national healthcare registers, were events. Outcomes were analysed as time-to-event, adjusted for Charlson Comorbidity Index and socioeconomic status. RESULTS: Five hundred and forty-one participants (92%) from each trial arm and 2705 unexposed men were included. We found no statistically significant differences between the radiotherapy groups (broad code sets: genitourinary events, adjusted hazard ratio 0.95, 95% confidence interval 0.71-1.25; gastrointestinal events, 1.24, 0.91-1.69). Compared with the unexposed men, 10-year excess cumulative incidence was 8% and 5% for genitourinary and 5% and 4% for gastrointestinal events when applying the broad and narrow code sets, respectively, without excess mortality events. CONCLUSION: The results support the HYPO-RT-PC findings by showing similar morbidity between ultra-hypofractionated and standard radiotherapy. Excess events were estimated to 4-8%, without increased associated mortality.
引用
- Persson AE, Kjellén E, Garmo H, et al. Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PC. Radiother Oncol. 2025. PMID: 41389860. doi:10.1016/j.radonc.2025.111323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。